Society of Diabetic Nephropathy Prevention Journal of Nephropathology 2251-8363 8 4 2019 10 01 Nephroprotection and chemotherapy sensitivity impact of metformin during cisplatin therapy; an updated review e45 e45 10.15171/jnp.2019.45 EN Mohsen Akhavan Sepahi https://orcid.org/0000-0002-0499-8475 Sarvenaz Mehrabi https://orcid.org/0000-0002-1916-0173 Rohollah Valizadeh https://orcid.org/0000-0002-1523-7604 Steven James Kellner Azin Mirzazadeh https://orcid.org/0000-0002-1656-1756 Semko Ebrahimi https://orcid.org/0000-0003-2391-0616 REVIEW 10.15171/jnp.2019.45 2019 08 07 2019 10 02 Chemotherapy has been accepted as the most common choice for cancer treatment. However, chemotherapy-induced toxicity and chemotherapy resistance are the two challenging barriers to the treatment. Metformin is a safe, inexpensive, and the first line drug to treat type II diabetes. It has also a significant anti-tumor effect with a selective cytotoxic efficacy on cancer stem cells. It also has renoprotective efficacy. The current study contributes to incorporating metformin to chemotherapeutic agents to develop treatment efficiency and reduce the chemotherapy-induced side-effects (such as toxicity and resistance) and also to benefit the nephroprotective impact of this drug.